Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 June;61(3) > Minerva Cardioangiologica 2013 June;61(3):323-31

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

ORIGINAL ARTICLES  


Minerva Cardioangiologica 2013 June;61(3):323-31

language: English

Mesoglycan treatment in Raynaud phenomenon: a case series

Di Biase A.

Ambulatory of Vascular Diagnostic, Geriatric Medicine Villa Verde, Taranto, Italy


PDF  


Aim and methods: Raynaud’s phenomenon (RP) is a common clinical disorder without cure or gold standard therapy. Mesoglycan is an well-balanced extract of glycosaminoglycans active on endothelial layers at microcirculatory level. Herein we investigated for the first time the efficacy and tolerability of mesoglycan on vasospastic attacks and videocapillaroscopy patterns in 25 consecutive patients with primary or secondary RP.
Results and conclusion: During 12 months of add-on therapy, mesoglycan obtained a remarkable and significant reduction in the frequency of Raynaud attacks and an improvement of the capillaroscopy abnormalities in most patients, without important adverse effects, revealing a good convenience in the management if this condition.

top of page

Publication History

Cite this article as

Corresponding author e-mail

a.dibiase@email.it